Abstract
Three main targets were subjected for the most approved monoclonal antibodies (mAbs) in cancer therapy: EGFR in solid cancer, the clusters of differentiation in blood cancer and VEGF in angiogenesis. Meanwhile side effects, the elevated costs and resistance problems are limiting the efficiency of mAbs as targeted therapy. The combinatory therapy with chemo or radiotherapy has improved the efficiency of mAbs. The present review aims to shed more light on the immunotherapy and the related patents that were developed for cancer treatment.
Keywords: Cetuximab, Panitumumab, Nimutuzumab, trastuzumab, retuximab, ibritumumab, tozutumumab, ofamumumab, alemtuzumab, gemtuzumumab, Brentuximab, bevacizumab, ipilimumab, Neoplasms, immunotherapy, combinatory, United States Food and Drug Administration, patents.
Recent Patents on Biotechnology
Title:Monoclonal Antibodies as Cancer Therapeutics
Volume: 6 Issue: 1
Author(s): Jihene Elloumi, Karim Jellali, Ikram Jemel and Sami Aifa
Affiliation:
Keywords: Cetuximab, Panitumumab, Nimutuzumab, trastuzumab, retuximab, ibritumumab, tozutumumab, ofamumumab, alemtuzumab, gemtuzumumab, Brentuximab, bevacizumab, ipilimumab, Neoplasms, immunotherapy, combinatory, United States Food and Drug Administration, patents.
Abstract: Three main targets were subjected for the most approved monoclonal antibodies (mAbs) in cancer therapy: EGFR in solid cancer, the clusters of differentiation in blood cancer and VEGF in angiogenesis. Meanwhile side effects, the elevated costs and resistance problems are limiting the efficiency of mAbs as targeted therapy. The combinatory therapy with chemo or radiotherapy has improved the efficiency of mAbs. The present review aims to shed more light on the immunotherapy and the related patents that were developed for cancer treatment.
Export Options
About this article
Cite this article as:
Elloumi Jihene, Jellali Karim, Jemel Ikram and Aifa Sami, Monoclonal Antibodies as Cancer Therapeutics, Recent Patents on Biotechnology 2012; 6 (1) . https://dx.doi.org/10.2174/187220812799789190
DOI https://dx.doi.org/10.2174/187220812799789190 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
Call for Papers in Thematic Issues
Advancements in Plant Genetics and Genomics
This thematic issue will highlight cutting-edge innovations and recent patents across the breadth of plant genetics and genomics. Key topics will include advanced breeding techniques, omics-based approaches, gene editing, trait discovery, and translational applications for crop improvement. Renowned researchers from leading institutions worldwide will provide state-of-the-art insights and future perspectives ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma
Current Cancer Drug Targets RANKL/RANK/OPG: Key Therapeutic Target in Bone Oncology
Current Drug Discovery Technologies Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators
Current Cancer Therapy Reviews Computational Drug Repositioning for Cancer Therapeutics
Current Topics in Medicinal Chemistry 3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors
Medicinal Chemistry Targeting the L-Arginine-Nitric Oxide Pathway for Cancer Treatment
Current Pharmaceutical Design Interfering with Hedgehog Pathway: New Avenues for Targeted Therapy in Rhabdomyosarcoma
Current Drug Targets Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Current Pharmaceutical Design γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Role of Active Drug Transporters in Refractory Multiple Myeloma
Current Topics in Medicinal Chemistry Recent Patents on Devices and Technologies for Early Cancer Diagnostics
Recent Patents on Biomedical Engineering (Discontinued) Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Current Pharmaceutical Biotechnology Molecular Monitoring of Immune Reconstitution After Haploidentical Stem Cell Transplantation
Current Stem Cell Research & Therapy Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Active-Targeted Nanotherapy Strategies for Prostate Cancer
Current Cancer Drug Targets Molecular Mechanism of Anti-tumor Effect by Triptolide in Hematological Malignancies
Current Signal Transduction Therapy Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets